• Enveric Biosciences initiated GLP genotoxicity studies for lead neuroplastogen EB-003 to support an IND filing and Phase 1 plans.
• No results have been presented; readouts are expected in the future as the IND-enabling package advances.
• Studies aim to clarify whether EB-003 poses genetic mutation risk, a key safety hurdle before first-in-human dosing.
• Update signals continued progress toward clinical entry for a non-hallucinogenic neuroplastogen positioned for depression and anxiety indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260602535123) on June 02, 2026, and is solely responsible for the information contained therein.